Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 41 of 948 for:    tablet | Japan

Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02835508
Recruitment Status : Completed
First Posted : July 18, 2016
Last Update Posted : January 11, 2017
Sponsor:
Information provided by (Responsible Party):
Janssen Pharmaceutical K.K.

Brief Summary:
The purpose of the study is to assess the safety and Pharmacokinetic (PK) profile of JNJ-56021927 and its active metabolite JNJ-56142060 after single-dose administration of 60 milligram (mg), 120 mg, and 240 mg JNJ-56021927 as the tablet formulation in healthy male Japanese participants.

Condition or disease Intervention/treatment Phase
Healthy Drug: JNJ-56021927 60 Milligram Drug: JNJ-56021927 120 Milligram Drug: JNJ-56021927 240 Milligram Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetic Profile of JNJ-56021927 When Administered as the Tablet Formulation in Healthy Male Japanese Subjects
Study Start Date : June 2016
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Arm Intervention/treatment
Experimental: Treatment A
Participants will receive a single dose of 1 tablet of JNJ-56021927, 60 milligram (mg) on Day 1.
Drug: JNJ-56021927 60 Milligram
JNJ-56021927 60 mg oral tablet.
Other Name: apalutamide

Experimental: Treatment B
Participants will receive a single dose of JNJ-56021927, 120 mg (2 tablets*60 mg) on Day 1.
Drug: JNJ-56021927 120 Milligram
JNJ-56021927 120 mg as 2 tablets of 60 mg.
Other Name: apalutamide

Experimental: Treatment C
Participants will receive a single dose of JNJ-56021927, 240 mg (4 tablets*60 mg) on Day 1.
Drug: JNJ-56021927 240 Milligram
JNJ-56021927 240 mg as 4 tablets of 60 mg.
Other Name: apalutamide




Primary Outcome Measures :
  1. Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Predose, Up to Day 57 ]
    Maximum observed plasma concentration (Cmax) will be assessed.

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Predose, Up to Day 57 ]
    Actual sampling time to reach maximum observed analyte concentration (Tmax) will be assessed.

  3. Area Under Concentration from time zero to the last quantifiable AUC (0-last) [ Time Frame: Predose, Up to Day 57 ]
    AUC from time zero to the last quantifiable concentration will be assessed.

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) [ Time Frame: Predose, Up to Day 57 ]
    The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC (0-last) and C (0-last)/lambda(z); wherein AUC (0-last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda (z) is elimination rate constant. AUC (0-infinity) will be assessed.

  5. Time to Last Quantifiable Plasma Concentration (Tlast) [ Time Frame: Predose, Up to Day 57 ]
    The Tlast, time to last observed quantifiable plasma concentration will be assessed.

  6. Percentage of Area Under the Plasma Concentration-Time Curve Extrapolated From Last Measurable Concentration to Infinite Time (%AUC,ext) [ Time Frame: Predose, Up to Day 57 ]
    Percentage of area under the plasma concentration-time curve extrapolated from last measurable concentration to infinite time (%AUC,ext) is calculated as (AUC [0-infinity] minus AUC [0-last])/ AUC [0-infinity])*100.

  7. Apparent Clearance (CL/F) [ Time Frame: Predose, Up to Day 57 ]
    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F will be calculated as CL/F = Dose/AUC [0-infinity]

  8. Apparent Terminal Elimination Half-life (t1/2term) [ Time Frame: Predose, Up to Day 57 ]
    Apparent terminal elimination half-life, calculated as 0.693/apparent terminal elimination rate constant (λz)

  9. Apparent Terminal Elimination Rate Constant (lambda z) [ Time Frame: Predose, Up to Day 57 ]
    Apparent terminal elimination rate constant, estimated by linear regression using the terminal log-linear phase of the log transformed concentration vs time data

  10. Apparent Volume of Distribution (Vd/F) [ Time Frame: Predose, Up to Day 57 ]
    Apparent volume of distribution based on the terminal phase following oral administration calculated as Vd/F = Dose/ apparent terminal elimination rate constant (λz)*AUC [0-infinity]

  11. Metabolite to Parent Drug Ratio for Maximum Observed Plasma Concentration (MPR Cmax) [ Time Frame: Predose, Up to Day 57 ]
    Metabolite to parent drug ratio for Cmax will be assessed.

  12. Metabolite to Parent Drug Ratio for Area Under Concentration from time zero to the last quantifiable concentration (MPR AUC [0-last]) [ Time Frame: Predose, Up to Day 57 ]
    Metabolite to parent drug ratio for AUC [0-last] will be assessed.

  13. Metabolite to Parent Drug Ratio for Area Under Curve from time zero extrapolated to infinity (MPR AUC [0-infinity]) [ Time Frame: Predose, Up to Day 57 ]
    Metabolite to parent drug ratio for AUC [0-infinity] will be assessed.

  14. Area Under Curve from time of administration to 24 hours post dosing [ Time Frame: Predose, Up to Day 57 ]
    AUC from time of administration to 24 hours post dosing will be assessed.

  15. Area Under Curve from time of administration to 168 hours post dosing [ Time Frame: Predose, Up to Day 57 ]
    AUC from time of administration to 168 hours post dosing will be assessed.


Secondary Outcome Measures :
  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Up to Day 57 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participant must have a body mass index between 18.0 and 29.9 Kilogram per meter square (kg/m^2), inclusive, and a body weight not less than 50 Kilogram (kg)
  • Participant must have a blood pressure between 90 and 140 Millimeters of Mercury (mm Hg) systolic, inclusive, and no higher than 90 mm Hg diastolic at screening
  • Participant must have a normal 12-lead Electrocardiogram (ECG) (based on the mean value of the triplicate parameters) consistent with normal cardiac conduction and function at screening, including: a) normal sinus rhythm (heart rate between 45 and 90 beats per minute, extremes included); b) QT interval corrected for heart rate according to Fridericia (QTcF) <= 450 milliseconds (ms); c) QRS interval less than or equal (<=)110 ms; d) PR interval <200 ms; e) ECG morphology consistent with healthy cardiac conduction and function
  • Participant must be a healthy Japanese male
  • Participant must agree to use an adequate contraception method as deemed appropriate by the investigator; to always use a condom during intercourse and to not donate sperm during the study and for 3 months after study drug administration

Exclusion Criteria:

  • Participant with a history of current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
  • Participant has donated blood or blood product or had substantial loss of blood more than 200 milliliter (mL) within 1 month before study drug administration, or greater than equal (>=) 400 mL within 3 months before study drug administration, or participant has donated a total volume of blood in the past one year exceeding 1200 mL, or participant has an intention to donate blood or blood products during the study and for at least 2 months after completion of the study
  • Participant has presence of sexual dysfunction (abnormal libido, erectile dysfunction, etc) or any medical condition that would affect sexual function
  • Participant has received an investigational drug including investigational vaccines or used an invasive investigational medical device within 3 months or within a period less than 10 times the drug's half-life, whichever is longer, before the planned study drug administration
  • Participant has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-hepatitis C virus {HCV}) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02835508


Locations
Layout table for location information
Japan
Kumamoto-Shi, Japan
Sponsors and Collaborators
Janssen Pharmaceutical K.K.
Investigators
Layout table for investigator information
Study Director: Janssen Pharmaceutical K.K. Clinical Trial Janssen Pharmaceutical K.K.

Layout table for additonal information
Responsible Party: Janssen Pharmaceutical K.K.
ClinicalTrials.gov Identifier: NCT02835508     History of Changes
Other Study ID Numbers: CR108165
56021927PCR1021 ( Other Identifier: Janssen Pharmaceutical K.K. )
First Posted: July 18, 2016    Key Record Dates
Last Update Posted: January 11, 2017
Last Verified: January 2017